Sign in
Not yet taking people in United StatesPhase 1/2

Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Bethesda, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
220 people, planned
Starts
23 Nov 2026
Expected to end
1 Nov 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001
  • Pvs230D1-EPA/Matrix-M
Record updated
18 November 2026

Who can take part

Age
18 years to 54 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (43)Hide the full registry criteria

Who cannot take part

  • Any prior confirmed P. vivax malaria diagnosis or clinical history consistent with P. vivax malaria diagnosis within the previous 5 years, at the investigator s discretion
  • History of anaphylaxis, severe allergy, or other concerning adverse reaction, in the opinion of the investigator, to a previous vaccine
  • Any of the following within the specified periods:; Chronic systemic immunosuppressive medications (>14 days) within 6 months of study day 0 (e.g., cytotoxic medications, adrenocorticotrophic hormone, or oral/parental corticosteroids equivalent to >0.5 mg/kg/day of prednisone); Investigational or non-FDA approved/authorized product or vaccine within 28 days prior to study day 0, or; Prior receipt of packed red cells or other blood products or immunoglobulins within 6 months of study day 0, or; Receipt of any vaccination less than 28 days before day 0
  • Investigational P. vivax malaria vaccine within the last 2 years with the exception of Pvs230D1-EPA/MM as part of NIH protocol 001501
  • Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study; Primary Vaccine Series Participants; An individual who meets any of the following criteria will be excluded from participation in this study:
  • History of travel to or residence in a P. vivax malaria endemic region for more than 2 weeks during the past 2 years
  • History of a severe reaction to arthropod bites, or history of anaphylaxis or severe unexpected allergy to any substance
  • History of alcohol use disorder (exceptions may be made at the investigator s discretion if they have completed treatment or are otherwise currently abstinent) or refusal to agree to refrain from drinking from the day of the challenge agent inoculation until completion of their antimalarial course; Booster Vaccine Participants; An individual who meets any of the following criteria will be excluded from participation in the optional CHMI-T component of the study:
  • History of a severe reaction to arthropod bites, or history of anaphylaxis or severe unexpected allergy to any substance
  • History of alcohol use disorder (exceptions may be made at the investigator s discretion if they have completed treatment or are otherwise currently abstinent) or refusal to agree to refrain from drinking from the day of the challenge agent inoculation until completion of their antimalarial course; Co-enrollment guidelines: Co-enrollment in other trials is restricted. Consideration for coenrollment, other than enrollment on trials evaluating the use of an investigational malaria vaccine as described above will require the approval of the principal investigator. Study staff should be notified of co-enrollment on any other protocol
  • For individuals of childbearing potential:; Currently breastfeeding; Currently pregnant as determined by history or a positive human choriogonadotropin (beta-hCG) test, urine or serum; Planning to become pregnant in the next 12 months
  • Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history including:; Screening blood test laboratory parameters outside of local lab normal range; Individuals may be included at the investigator s discretion for not clinically significant values outside of normal range; In the event of abnormal test results, confirmatory repeat tests will be requested, at the investigator s discretion; HIV, hepatitis B, and/or hepatitis C as determined by HIV antigen/antibody, Hepatitis B surface antigen, and anti-Hepatitis C antibody laboratory tests, respectively; Immunodeficiency including asplenia or functional asplenia or significant autoimmune disease
  • Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history including:; Retinal disease, visual field changes, psoriasis, porphyria, or known allergy to chloroquine or artemether/lumefantrine; Cardiac disease including >10% cardiovascular risk as determined by the nonlaboratory method described by Gaziano or an abnormal EKG demonstrating a corrected QT interval by Fridericia s (QTcF) formula of >450 msec or other concerning arrhythmia
  • Current or planned use of medications known to significantly prolong the QT interval or otherwise interfere with study agents
  • Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history including:; Retinal disease, visual field changes, psoriasis, porphyria, or known allergy to chloroquine or artemether/lumefantrine; Cardiac disease including >10% cardiovascular risk as determined by the nonlaboratory method described by Gaziano or an abnormal EKG demonstrating a corrected QTcF of >450 msec or other concerning arrhythmia. For participants not undergoing CHMI-T after booster vaccine, no EKG will be required
  • Current or planned use of medications known to significantly prolong the QT interval or otherwise interfere with study agents
  • All Participants
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Planned travel to a malaria-endemic area (see https://www.cdc.gov/malaria/travelers/country_table/a.html) until 6-months beyond the final vaccination; --Exceptions may be made, at the investigator s discretion, if the travel is limited to areas without appreciable levels of P. vivax transmission
  • Any individual without good peripheral venous access, at the investigator s discretion
  • Being a current or former study team member or clinical trial staff with direct involvement of the trial or being an employee supervised by a study team member
  • For individuals of childbearing potential:; --Rh blood group negative
  • Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the duration of admission. Participants may smoke up to 5 cigarettes or equivalent per day for the rest of the study (by attestation), at investigators discretion
  • For individuals of childbearing potential:; --Rh blood group negative
  • Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the duration of admission. Participants may smoke up to 5 cigarettes or equivalent per day for the rest of the study (by attestation)

Other criteria

  • INCLUSION CRITERIA:; All Participants; In order to participate in this study, an individual must meet all of the following criteria:
  • Age >=18 and <=54 years at the time of enrollment in this protocol, or for booster participants, at the time of enrollment into NIH protocol 001501
  • In good general health and without clinically significant medical history
  • Able to provide informed consent
  • Study comprehension exam passed (a score of >=80% or per investigator's discretion) prior to study activities
  • Individuals of childbearing potential must agree to use an acceptable method of contraception from 1 month prior to day 0 to 1 month after completion of anti-malarial treatment. Participants who receive only the booster vaccination need only agree to use contraception from 1 month prior to day 0 to 1 month after the booster vaccination; Acceptable methods of contraception include the following:
  • A barrier method (e.g., consistent condom use) combined with an oral contraceptive pill, hormonal patch, or ring
  • Parenteral hormonal contraceptive implant or an intrauterine device; Participants who otherwise are not at risk of becoming pregnant, at the judgement of the investigator will not be required to use contraception. Such participants may include those:
  • Having undergone hysterectomy, bilateral oophorectomy, or bilateral fallopian tube ligation
  • Having reached menopause (age >=45 years plus no menses for 12 consecutive months without an alternative medical cause)
  • Having exclusive same-sex relations or committed longstanding abstinence due to a serious life choice
  • Having an exclusive male partner who has undergone vasectomy at least 4 months prior; Suitable accommodation and reliable access to the NIHCC for the duration of the study, in the opinion of the investigator; Willing to allow long-term storage of study samples for future research; Primary Vaccine Series with CHMI-T Participants; In order to participate in this study an individual must meet all of the following criteria:
  • RBCs positive for Duffy antigen/chemokine receptor
  • Willing to refrain from donating blood throughout the study until 3 years after completion of anti-malarial treatment; Booster Vaccine Participants; In order to participate in this study an individual must meet all of the following criteria:
  • Has received all 3 doses of the primary vaccine series as a part of NIH protocol 001501 with the 3rd dose occurring no less than 12 months prior to intended enrollment
  • Willing to refrain from donating blood throughout the study until 6 months after the booster vaccination; The following additional criteria must be met in order to for participants to undergo optional CHMI-T:
  • Willing to refrain from donating blood throughout the study until 3 years after completion of anti-malarial treatment
  • RBCs positive for Duffy antigen/chemokine receptor

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Malaria or plasmodium vivax

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Shanan Immel, M.D.Not yet recruiting

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Malaria is a disease caused by parasites spread by mosquito bites. Researchers want to test a vaccine that could stop mosquitoes from picking up these parasites when they bite infected people. This could stop malaria from spreading.

Objective:

To test a study vaccine (Pvs230D1-EPA/MM) to stop malaria transmission in healthy adults.

Eligibility:

Healthy people aged 18 to 54 years. People who already received the vaccine during a different study are also needed.

Design:

Participants will be screened. They will have a physical exam. They will have blood tests and a test of their heart function (a simple electrocardiogram or EKG).

The vaccine is given as an injectionin the upper arm. Participants who have never gotten the study vaccine will get 3 vaccines; each injection will be about 1 month apart. Participants who were vaccinated before will receive only 1 vaccine for this study. All participants will have multiple phone and in-person follow-up visits after each vaccination.

Two to 12 weeks after their last vaccine, all participants will be injected with live malaria parasites. Then they will be seenin the clinic for about 3 days. They will be monitored daily until they develop symptoms of malaria, usually in about 10 days then will be admitted to the NIH hospital.

While in the NIH hospital, participants will have 3 mosquito feedings: Two cups containing mosquitoes will be placed on an arm or leg. The mosquitoes will feed for about 15 minutes. Participants will receive medicines to relieve discomfort from the bites.

Participants will then be treated for malaria. They will have follow-up visits and calls until they fully recover.

The 3 groups in the trial

  • Booster VaccineTreatment being tested

    A fourth (booster) dose of of Pvs230D1-EPA/MM will be given to participants who previously received the primary vaccine series while enrolled in NIH protocol 001501, at a dose identical to that which the participant received under NIH Protocol 1501 (i.e., 5microg Pvs230D1-EPA/50microg MM, 25microg Pvs230D1-EPA/50microg MM, or 50microg Pvs230D1-EPA/50microg MM).Optionally, two to twelve weeks after the final vaccination, challenge agent derived from a cell bank of cryopreserved blood-stage P. vivax (PvHMB-CCE001) will be administered intravenously (IV). Participants will be monitored and admitted to the NIHCC to undergo safety monitoring, transmission assays, and receive antimalarial treatment.

    Treatment: Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001 and Pvs230D1-EPA/Matrix-M

  • Open-label controlExisting treatment, for comparison

    Participants enrolled on NIH protocol 001970, Induced blood-stage malaria in healthy malaria-naive adults to assess the safety and infectivity of Plasmodium vivax challenge agent and evaluate transmission in mosquito feeding assays , will serve as open-label controls.

    Treatment: Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001

  • Primary Vaccine SeriesTreatment being tested

    Three doses of 5microg Pvs230D1-EPA/50microg MM will be administered at 1-month intervals, via intramuscular (IM) injection. Two to twelve weeks after the final vaccination, challenge agent derived from a cell bank of cryopreserved blood-stage P. vivax (PvHMB-CCE001) will be administered intravenously (IV). Participants will be monitored and admitted to the NIHCC to undergo safety monitoring, transmission assays, and receive antimalarial treatment.

    Treatment: Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001 and Pvs230D1-EPA/Matrix-M

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2 Study of Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model
Criteria questions
Built from NCT07930585, who can take part
Record updated
18 November 2026